Clinical Trial

Biomarkers of Steatohepatitis in Type 2 Diabetes Patients

Study acronym: STEDIB
Completed
View on ClinicalTrials.gov →
Summary
The aims of the study are to identify a subgroup of type 2 diabetics at risk of developing and progressing to non-alcoholic steatohepatitis (NASH), to correlate clinical and laboratory parameters with sonographic and elastographic findings in order to pinpoint indicators of liver fibrosis (NASH), and to facilitate targeted screening and intensified management of type 2 diabetes mellitus to prevent NASH complications.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-31.
Status change: Not Yet Recruiting → Completed 2026-06-06
Trial Details
NCT Number NCT07098520
Lead Sponsor Faculty Hospital Kralovske Vinohrady
Conditions Diabetes, Steatosis of Liver
Enrollment 40 participants
Start Date 2025-09-01
Primary Completion 2026-03-30 (estimated)
Study Completion 2026-06-05 (estimated)
Updated on ClinicalTrials.gov 2026-06-10